[Skip to Navigation]
Invited Commentary
Less Is More
February 24, 2020

Deprescribing Proton Pump Inhibitors: Overcoming Resistance

Author Affiliations
  • 1Clinical Practice Assessment Unit, Department of Medicine, McGill University Health Centre, Montreal, Quebec, Canada
  • 2Division of General Internal Medicine, Department of Medicine, McGill University, Montreal, Quebec, Canada
  • 3Division of Infectious Diseases, Department of Medicine, McGill University, Montreal, Quebec, Canada
  • 4McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada
JAMA Intern Med. 2020;180(4):571-573. doi:10.1001/jamainternmed.2020.0040

Proton pump inhibitors (PPIs) are a successful class of medications accounting for $79 billion spent in the United States between 2007 and 2011.1 While many PPI indications involve limited or short-term use, it is not uncommon for patients to use them for extended periods or for clinicians to prescribe them for indications not supported by robust evidence of efficacy. While PPIs are generally safe, even rare infectious and noninfectious adverse events2 are important on a population level given their wide use.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words